SlideShare a Scribd company logo
HYPERTENSION
DR. GORDHAN DAS
FCPS
Problem Magnitude
 Hypertension( HTN) is the most common
primary diagnosis in America.
 35 million office visits are as the primary
diagnosis of HTN.
 50 million or more Americans have high BP.
 Worldwide prevalence estimates for HTN may be
as much as 1 billion.
 7.1 million deaths per year may be attributable to
hypertension.
Definition
 A systolic blood pressure ( SBP) >139
mmHg and/or
 A diastolic (DBP) >89 mmHg.
 Based on the average of two or more
properly measured, seated BP
readings.
 On each of two or more office visits.
Accurate Blood Pressure Measurement
 The equipment should be regularly inspected and
validated.
 The operator should be trained and regularly retrained.
 The patient must be properly prepared and positioned
and seated quietly for at least 5 minutes in a chair.
 The auscultatory method should be used.
 Caffeine, exercise, and smoking should be
avoided for at least 30 minutes before BP
measurement.
 An appropriately sized cuff should be used.
BP Measurement
 At least two measurements should be
made and the average recorded.
 Clinicians should provide to patients
their specific BP numbers and the BP
goal of their treatment.
Follow-up based on initial BP
measurements for adults*
*Without acute end-organ damagewww.nhlbi.nih.gov
Classification
www.nhlbi.nih.gov
Prehypertension
 SBP >120 mmHg and <139mmHg and/or
 DBP >80 mmHg and <89 mmHg.
 Prehypertension is not a disease category
rather a designation for individuals at high risk
of developing HTN.
Pre-HTN
 Individuals who are prehypertensive are not
candidates for drug therapy but
 Should be firmly and unambiguously advised to
practice lifestyle modification
 Those with pre-HTN, who also have diabetes
or kidney disease, drug therapy is indicated if a
trial of lifestyle modification fails to reduce their
BP to 130/80 mmHg or less.
Isolated Systolic Hypertension
 Not distinguished as a separate entity as
far as management is concerned.
 SBP should be primarily considered
during treatment and not just diastolic BP.
 Systolic BP is more important
cardiovascular risk factor after age 50.
 Diastolic BP is more important before age
50.
Frequency Distribution of Untreated HTN by Age
Isolated Systolic
HTN
Isolated Diastolic
HTN
Systolic Diastolic
HTN
Hypertensive Crises
 Hypertensive Urgencies: No
progressive target-organ dysfunction.
(Accelerated Hypertension)
 Hypertensive Emergencies:
Progressive end-organ dysfunction.
(Malignant Hypertension)
Hypertensive Urgencies
 Severe elevated BP in the upper
range of stage II hypertension.
 Without progressive end-organ
dysfunction.
 Examples: Highly elevated BP without
severe headache, shortness of breath or
chest pain.
 Usually due to under-controlled HTN.
Hypertensive Emergencies
 Severely elevated BP (>180/120mmHg).
 With progressive target organ dysfunction.
 Require emergent lowering of BP.
 Examples: Severely elevated BP with:
Hypertensive encephalopathy
Acute left ventricular failure with pulmonary
edema
Acute MI or unstable angina pectoris
Dissecting aortic aneurysm
Types of Hypertension
 Primary HTN:
also known as
essential HTN.
accounts for 95%
cases of HTN.
no universally
established cause
known.
 Secondary HTN:
less common cause
of HTN ( 5%).
secondary to other
potentially rectifiable
causes.
Causes of Secondary HTN
 Common
 Intrinsic renal disease
 Renovascular disease
 Mineralocorticoid
excess
 Sleep Breathing
disorder
 Uncommon
 Pheochromocytoma
 Glucocorticoid excess
 Coarctation of Aorta
 Hyper/hypothyroidism
Secondary HTN-Clues in Medical
History
 Onset: at age < 30 yrs ( Fibromuscular dysplasi)
or > 55 (athelosclerotic renal artery stenosis),
sudden onset (thrombus or cholesterol
embolism).
 Severity: Grade II, unresponsive to treatment.
 Episodic, headache and chest pain/palpitation
(pheochromocytoma, thyroid dysfunction).
 Morbid obesity with history of snoring and
daytime sleepiness (sleep disorders)
Secondary HTN-clues on Exam
 Pallor, edema, other signs of renal
disease.
 Abdominal bruit especially with a diastolic
component (renovascular)
 Truncal obesity, purple striae, buffalo
hump (hypercortisolism)
Secondary HTN-Clues on Routine
Labs
 Increased creatinine, abnormal urinalysis
( renovascular and renal
parenchymal disease)
 Unexplained hypokalemia
(hyperaldosteronism)
 Impaired blood glucose
( hypercortisolism)
 Impaired TFT (Hypo-/hyper- thyroidism)
Secondary HTN-Screening
Tests
www.nhlbi.nih.gov
Renal Parenchymal Disease
 Common cause of secondary HTN (2-5%)
 HTN is both cause and consequence of
renal disease
 Multifactorial cause for HTN including
disturbances in Na/water balance,
vasodepressors/ prostaglandins
imbalance
 Renal disease from multiple etiologies.
Renovascular HTN
 Atherosclerosis 75-90% ( more common in older
patients)
 Fibromuscular dysplasia 10-25% (more
common in young patients, especially females)
 Other
• Aortic/renal dissection
• Takayasu’s arteritis
• Thrombotic/cholesterol emboli
• CVD
• Post transplantation stenosis
• Post radiation
Complications of Prolonged
Uncontrolled HTN
 Changes in the vessel wall leading to
vessel trauma and arteriosclerosis
throughout the vasculature
 Complications arise due to the “target
organ” dysfunction and ultimately failure.
 Damage to the blood vessels can be seen
on fundoscopy.
Target Organs
 CVS (Heart and Blood Vessels)
 The kidneys
 Nervous system
 The Eyes
Effects On CVS
 Ventricular hypertrophy, dysfunction and
failure.
 Arrhithymias
 Coronary artery disease, Acute MI
 Arterial aneurysm, dissection, and
rupture.
Effects on The Kidneys
 Glomerular sclerosis leading to impaired
kidney function and finally end stage
kidney disease.
 Ischemic kidney disease especially when
renal artery stenosis is the cause of HTN
Nervous System
 Stroke, intracerebral and subaracnoid
hemorrhage.
 Cerebral atrophy and dementia
The Eyes
 Retinopathy, retinal hemorrhages and
impaired vision.
 Vitreous hemorrhage, retinal detachment
 Neuropathy of the nerves leading to
extraoccular muscle paralysis and
dysfunction
Retina Normal and Hypertensive
Retinopathy
Normal Retina Hypertensive Retinopathy A: Hemorrhages
B: Exudates (Fatty Deposits)
C: Cotton Wool Spots (Micro
Strokes)
A B
C
Stage I- Arteriolar Narrowing
Arteriolar Narrowing
Stage II- AV Nicking
AV Nicking
AV Nicking
AV Nicking
AV Nicking
Stage III- Hemorrhages (H), Cotton
Wool Spots and Exudats (E)
H
E
Stage IV- Stage III+Papilledema
Patient Evaluation Objectives
 (1) To assess lifestyle and identify other
cardiovascular risk factors or concomitant
disorders that may affect prognosis and guide
treatment
 (2) To reveal identifiable causes of high BP
 (3) To assess the presence or absence of
target organ damage and CVD
(1) Cardiovascular Risk factors
 Hypertension
 Cigarette smoking
 Obesity (body mass index 30 kg/m2)≥
 Physical inactivity
 Dyslipidemia
 Diabetes mellitus
 Microalbuminuria or estimated GFR <60 mL/min
 Age (older than 55 for men, 65 for women)
 Family history of premature cardiovascular disease (men
under age 55 or women under age 65)
(2) Identifiable Causes of HTN
 Sleep apnea
 Drug-induced or related causes
 Chronic kidney disease
 Primary aldosteronism
 Renovascular disease
 Chronic steroid therapy and Cushing’s
syndrome
 Pheochromocytoma
 Coarctation of the aorta
 Thyroid or parathyroid disease
(3) Target Organ Damage
 Heart
Left ventricular hypertrophy
Angina or prior myocardial infarction
Prior coronary revascularization
Heart failure
 Brain
Stroke or transient ischemic attack
 Chronic kidney disease
 Peripheral arterial disease
 Retinopathy
History
 Angina/MI Stroke: Complications of HTN,
Angina may improve with b-blokers
 Asthma, COPD: Preclude the use of b-
blockers
 Heart failure: ACE inhibitors indication
 DM: ACE preferred
 Polyuria and nocturia: Suggest renal
impairment
History-contd.
 Claudication: May be aggravated by b-
blockers, atheromatous RAS may be present
 Gout: May be aggravated by diuretics
 Use of NSAIDs: May cause or aggravate HTN
 Family history of HTN: Important risk factor
 Family history of premature death: May
have been due to HTN
History-contd.
 Family history of DM : Patient may
also be Diabetic
 Cigarette smoker: Aggravate HTN,
independently a risk factor for CAD and
stroke
 High alcohol: A cause of HTN
 High salt intake: Advice low salt intake
Examination
 Appropriate measurement of BP in both arms
 Optic fundi
 Calculation of BMI ( waist circumference also
may be useful)
 Auscultation for carotid, abdominal, and femoral
bruits
 Palpation of the thyroid gland.
Examination-contd.
 Thorough examination of the heart and
lungs
 Abdomen for enlarged kidneys, masses,
and abnormal aortic pulsation
 Lower extremities for edema and pulses
 Neurological assessment
Routine Labs
 EKG.
 Urinalysis.
 Blood glucose and hematocrit; serum
potassium, creatinine ( or estimated GFR),
and calcium.
 HDL cholesterol, LDL cholesterol, and
triglycerides.
 Optional tests
urinary albumin excretion.
albumin/creatinine ratio.
Goals of Treatment
 Treating SBP and DBP to targets that are
<140/90 mmHg
 Patients with diabetes or renal disease, the BP
goal is <130/80 mmHg
 The primary focus should be on attaining the
SBP goal.
 To reduce cardiovascular and renal morbidity
and mortality
Benefits of Treatment
 Reductions in stroke incidence,
averaging 35–40 percent
 Reductions in MI, averaging 20–25
percent
 Reductions in HF, averaging >50 percent.
Lifestyle modifications
www.nhlbi.nih.gov
Lifestyle Changes Beneficial in Reducing Weight
 Decrease time in sedentary behaviors
such as watching television, playing video
games, or spending time online.
 Increase physical activity such as walking,
biking, aerobic dancing, tennis, soccer,
basketball, etc.
 Decrease portion sizes for meals and
snacks.
 Reduce portion sizes or frequency of
consumption of calorie containing beverages.
DASH Diet
 Dietary approaches to Stop Hypertension
 As effective as one medication
JNC 7 Reference Card

More Related Content

What's hot

Hypertension 2014 update
Hypertension 2014 updateHypertension 2014 update
Hypertension 2014 update
abualbd
 
Hypertension
HypertensionHypertension
Hypertension
Bibhash Kumar
 
Hypertension - Approach & Management
Hypertension - Approach & ManagementHypertension - Approach & Management
Hypertension - Approach & Management
Dr. Mohammed Sadiq Azam M.D.
 
Hypertension
Hypertension Hypertension
Hypertension
Amardeep Kumar
 
Hypertension- Classics Trobaugh
Hypertension- Classics TrobaughHypertension- Classics Trobaugh
Hypertension- Classics Trobaughpkhohl
 
Hypertension (HTN)
Hypertension (HTN)Hypertension (HTN)
Hypertension (HTN)
mahadev deuja
 
Hypertension: New Concepts, Guidelines, and Clinical Management Hypertensio...
Hypertension: New Concepts, Guidelines, and Clinical Management 	 Hypertensio...Hypertension: New Concepts, Guidelines, and Clinical Management 	 Hypertensio...
Hypertension: New Concepts, Guidelines, and Clinical Management Hypertensio...MedicineAndFamily
 
Hypertension
HypertensionHypertension
Hypertension
Ramachandra Barik
 
Hypertension management for primary health care
Hypertension management for primary health careHypertension management for primary health care
Hypertension management for primary health care
Khaled AlKhodari
 
Hypertension, its causes, types and management
Hypertension, its causes, types and managementHypertension, its causes, types and management
Hypertension, its causes, types and management
Abu Bakar
 
management of hypertension
management of hypertensionmanagement of hypertension
management of hypertension
pawan kumar
 
JNC 8 REVIEW AND SOME CASES OF SECONDARY HYPERTENSION
JNC 8 REVIEW AND SOME CASES OF SECONDARY HYPERTENSIONJNC 8 REVIEW AND SOME CASES OF SECONDARY HYPERTENSION
JNC 8 REVIEW AND SOME CASES OF SECONDARY HYPERTENSION
Sathiyamoorthy Veerasamy
 
New Hypertension Guidelines
New Hypertension GuidelinesNew Hypertension Guidelines
New Hypertension Guidelines
magdy elmasry
 
Hypertension diagnosis
Hypertension diagnosisHypertension diagnosis
Hypertension diagnosisBasem Enany
 
Hypertension Management
Hypertension Management Hypertension Management
Hypertension Management
Aparna Chaudhary
 
Hypertension Management
Hypertension ManagementHypertension Management
Hypertension Management
Marjanul Alam
 
Hypertension
Hypertension Hypertension
Hypertension
qbank org
 
ESC/ESH 2018
ESC/ESH 2018ESC/ESH 2018
ESC/ESH 2018
desktoppc
 

What's hot (20)

Hypertension 2014 update
Hypertension 2014 updateHypertension 2014 update
Hypertension 2014 update
 
Hypertension evaluation 1
Hypertension   evaluation 1Hypertension   evaluation 1
Hypertension evaluation 1
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension - Approach & Management
Hypertension - Approach & ManagementHypertension - Approach & Management
Hypertension - Approach & Management
 
Hypertension
Hypertension Hypertension
Hypertension
 
Hypertension- Classics Trobaugh
Hypertension- Classics TrobaughHypertension- Classics Trobaugh
Hypertension- Classics Trobaugh
 
Hypertension (HTN)
Hypertension (HTN)Hypertension (HTN)
Hypertension (HTN)
 
Hypertension: New Concepts, Guidelines, and Clinical Management Hypertensio...
Hypertension: New Concepts, Guidelines, and Clinical Management 	 Hypertensio...Hypertension: New Concepts, Guidelines, and Clinical Management 	 Hypertensio...
Hypertension: New Concepts, Guidelines, and Clinical Management Hypertensio...
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension management for primary health care
Hypertension management for primary health careHypertension management for primary health care
Hypertension management for primary health care
 
Hypertension+clinical
Hypertension+clinicalHypertension+clinical
Hypertension+clinical
 
Hypertension, its causes, types and management
Hypertension, its causes, types and managementHypertension, its causes, types and management
Hypertension, its causes, types and management
 
management of hypertension
management of hypertensionmanagement of hypertension
management of hypertension
 
JNC 8 REVIEW AND SOME CASES OF SECONDARY HYPERTENSION
JNC 8 REVIEW AND SOME CASES OF SECONDARY HYPERTENSIONJNC 8 REVIEW AND SOME CASES OF SECONDARY HYPERTENSION
JNC 8 REVIEW AND SOME CASES OF SECONDARY HYPERTENSION
 
New Hypertension Guidelines
New Hypertension GuidelinesNew Hypertension Guidelines
New Hypertension Guidelines
 
Hypertension diagnosis
Hypertension diagnosisHypertension diagnosis
Hypertension diagnosis
 
Hypertension Management
Hypertension Management Hypertension Management
Hypertension Management
 
Hypertension Management
Hypertension ManagementHypertension Management
Hypertension Management
 
Hypertension
Hypertension Hypertension
Hypertension
 
ESC/ESH 2018
ESC/ESH 2018ESC/ESH 2018
ESC/ESH 2018
 

Similar to Hypertension

Hypertension
HypertensionHypertension
Hypertension
Shaan Negi
 
HYPERTENSION (4).ppt
HYPERTENSION (4).pptHYPERTENSION (4).ppt
HYPERTENSION (4).ppt
jiregnaetichadako
 
HTN
HTNHTN
2.6. HTN.pptx
2.6. HTN.pptx2.6. HTN.pptx
2.6. HTN.pptx
AmareDejene
 
Hypertension
HypertensionHypertension
Hypertension
salman habeeb
 
Hypertension
HypertensionHypertension
Accerlerated hypertension
Accerlerated hypertensionAccerlerated hypertension
Accerlerated hypertensionSachin Verma
 
Hypertension
HypertensionHypertension
Hypertension
Sameen Rashid
 
Hypertension.pptx
Hypertension.pptxHypertension.pptx
Hypertension.pptx
SnigdhaGomber
 
HYPERTENSION.ppt
HYPERTENSION.pptHYPERTENSION.ppt
HYPERTENSION.ppt
ssuser642fe3
 
Hypertension
HypertensionHypertension
Hypertension
yuyuricci
 
Essential Hypertension
Essential Hypertension Essential Hypertension
Essential Hypertension
raheef
 
Systemic hypertension
Systemic hypertensionSystemic hypertension
Systemic hypertension
OPTOM FASLU MUHAMMED
 
HYPERTENSION.pptx
HYPERTENSION.pptxHYPERTENSION.pptx
HYPERTENSION.pptx
MishiSoza
 
Hypertension
HypertensionHypertension
HTN.pptx
HTN.pptxHTN.pptx
Systemic Hypertension
Systemic HypertensionSystemic Hypertension
Systemic Hypertension
Jawid786
 

Similar to Hypertension (20)

Hypertension
HypertensionHypertension
Hypertension
 
HYPERTENSION (4).ppt
HYPERTENSION (4).pptHYPERTENSION (4).ppt
HYPERTENSION (4).ppt
 
HTN
HTNHTN
HTN
 
2.6. HTN.pptx
2.6. HTN.pptx2.6. HTN.pptx
2.6. HTN.pptx
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension
HypertensionHypertension
Hypertension
 
Accerlerated hypertension
Accerlerated hypertensionAccerlerated hypertension
Accerlerated hypertension
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension.pptx
Hypertension.pptxHypertension.pptx
Hypertension.pptx
 
HYPERTENSION.ppt
HYPERTENSION.pptHYPERTENSION.ppt
HYPERTENSION.ppt
 
Hypertension
HypertensionHypertension
Hypertension
 
Essential Hypertension
Essential Hypertension Essential Hypertension
Essential Hypertension
 
Systemic hypertension
Systemic hypertensionSystemic hypertension
Systemic hypertension
 
HYPERTENSION.pptx
HYPERTENSION.pptxHYPERTENSION.pptx
HYPERTENSION.pptx
 
Hypertension
HypertensionHypertension
Hypertension
 
HTN.pptx
HTN.pptxHTN.pptx
HTN.pptx
 
HTN presentation
HTN presentationHTN presentation
HTN presentation
 
Systemic Hypertension
Systemic HypertensionSystemic Hypertension
Systemic Hypertension
 

More from Gordhan Das asani

ATN
ATNATN
Atn
AtnAtn
Nephrotic syndrome
Nephrotic syndromeNephrotic syndrome
Nephrotic syndrome
Gordhan Das asani
 
Ada 2018
Ada 2018Ada 2018
Heartfailuremodified 090721100845-phpapp01
Heartfailuremodified 090721100845-phpapp01Heartfailuremodified 090721100845-phpapp01
Heartfailuremodified 090721100845-phpapp01
Gordhan Das asani
 
Ihd 2
Ihd 2Ihd 2
Clairenephroticandnephriticsyndrome1 150218105627-conversion-gate01
Clairenephroticandnephriticsyndrome1 150218105627-conversion-gate01Clairenephroticandnephriticsyndrome1 150218105627-conversion-gate01
Clairenephroticandnephriticsyndrome1 150218105627-conversion-gate01
Gordhan Das asani
 
Nephrorounds3 2015final-150907110921-lva1-app6892
Nephrorounds3 2015final-150907110921-lva1-app6892Nephrorounds3 2015final-150907110921-lva1-app6892
Nephrorounds3 2015final-150907110921-lva1-app6892
Gordhan Das asani
 
Chronic kidney-disease-1216842299045729-8 (1)
Chronic kidney-disease-1216842299045729-8 (1)Chronic kidney-disease-1216842299045729-8 (1)
Chronic kidney-disease-1216842299045729-8 (1)
Gordhan Das asani
 
Nephro
NephroNephro
Toxico overdose-lec07-1223099219105884-9
Toxico overdose-lec07-1223099219105884-9Toxico overdose-lec07-1223099219105884-9
Toxico overdose-lec07-1223099219105884-9
Gordhan Das asani
 
Organophosphorouspoisoning 160727123533
Organophosphorouspoisoning 160727123533Organophosphorouspoisoning 160727123533
Organophosphorouspoisoning 160727123533
Gordhan Das asani
 
Presentation1
Presentation1Presentation1
Presentation1
Gordhan Das asani
 
Cushingsyndromeandaddisondisease 130618105538-phpapp01
Cushingsyndromeandaddisondisease 130618105538-phpapp01Cushingsyndromeandaddisondisease 130618105538-phpapp01
Cushingsyndromeandaddisondisease 130618105538-phpapp01
Gordhan Das asani
 
Vasculitis 130522234019-phpapp02
Vasculitis 130522234019-phpapp02Vasculitis 130522234019-phpapp02
Vasculitis 130522234019-phpapp02
Gordhan Das asani
 
Gout
GoutGout

More from Gordhan Das asani (20)

ATN
ATNATN
ATN
 
Atn
AtnAtn
Atn
 
Nephrotic syndrome
Nephrotic syndromeNephrotic syndrome
Nephrotic syndrome
 
Ada 2018
Ada 2018Ada 2018
Ada 2018
 
Heartfailuremodified 090721100845-phpapp01
Heartfailuremodified 090721100845-phpapp01Heartfailuremodified 090721100845-phpapp01
Heartfailuremodified 090721100845-phpapp01
 
HEART FAILURE
HEART FAILUREHEART FAILURE
HEART FAILURE
 
Ihd 2
Ihd 2Ihd 2
Ihd 2
 
IHD
IHDIHD
IHD
 
Clairenephroticandnephriticsyndrome1 150218105627-conversion-gate01
Clairenephroticandnephriticsyndrome1 150218105627-conversion-gate01Clairenephroticandnephriticsyndrome1 150218105627-conversion-gate01
Clairenephroticandnephriticsyndrome1 150218105627-conversion-gate01
 
Nephrorounds3 2015final-150907110921-lva1-app6892
Nephrorounds3 2015final-150907110921-lva1-app6892Nephrorounds3 2015final-150907110921-lva1-app6892
Nephrorounds3 2015final-150907110921-lva1-app6892
 
Chronic kidney-disease-1216842299045729-8 (1)
Chronic kidney-disease-1216842299045729-8 (1)Chronic kidney-disease-1216842299045729-8 (1)
Chronic kidney-disease-1216842299045729-8 (1)
 
Nephro
NephroNephro
Nephro
 
Toxico overdose-lec07-1223099219105884-9
Toxico overdose-lec07-1223099219105884-9Toxico overdose-lec07-1223099219105884-9
Toxico overdose-lec07-1223099219105884-9
 
Organophosphorouspoisoning 160727123533
Organophosphorouspoisoning 160727123533Organophosphorouspoisoning 160727123533
Organophosphorouspoisoning 160727123533
 
Presentation1
Presentation1Presentation1
Presentation1
 
Cushingsyndromeandaddisondisease 130618105538-phpapp01
Cushingsyndromeandaddisondisease 130618105538-phpapp01Cushingsyndromeandaddisondisease 130618105538-phpapp01
Cushingsyndromeandaddisondisease 130618105538-phpapp01
 
Vasculitis 130522234019-phpapp02
Vasculitis 130522234019-phpapp02Vasculitis 130522234019-phpapp02
Vasculitis 130522234019-phpapp02
 
Gout
GoutGout
Gout
 
SLE
SLESLE
SLE
 
RA
RARA
RA
 

Recently uploaded

Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Savita Shen $i11
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
Shweta
 
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
Catherine Liao
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
Levi Shapiro
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
د.محمود نجيب
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
Anurag Sharma
 
heat stroke and heat exhaustion in children
heat stroke and heat exhaustion in childrenheat stroke and heat exhaustion in children
heat stroke and heat exhaustion in children
SumeraAhmad5
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
LanceCatedral
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
GL Anaacs
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
NephroTube - Dr.Gawad
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
bkling
 
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyayaCharaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Dr KHALID B.M
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
addon Scans
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
greendigital
 
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in StockFactory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
rebeccabio
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
DrSathishMS1
 
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
i3 Health
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
MedicoseAcademics
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Saeid Safari
 

Recently uploaded (20)

Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
 
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
 
heat stroke and heat exhaustion in children
heat stroke and heat exhaustion in childrenheat stroke and heat exhaustion in children
heat stroke and heat exhaustion in children
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
 
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyayaCharaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
 
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in StockFactory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
 
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
 

Hypertension

  • 2. Problem Magnitude  Hypertension( HTN) is the most common primary diagnosis in America.  35 million office visits are as the primary diagnosis of HTN.  50 million or more Americans have high BP.  Worldwide prevalence estimates for HTN may be as much as 1 billion.  7.1 million deaths per year may be attributable to hypertension.
  • 3. Definition  A systolic blood pressure ( SBP) >139 mmHg and/or  A diastolic (DBP) >89 mmHg.  Based on the average of two or more properly measured, seated BP readings.  On each of two or more office visits.
  • 4. Accurate Blood Pressure Measurement  The equipment should be regularly inspected and validated.  The operator should be trained and regularly retrained.  The patient must be properly prepared and positioned and seated quietly for at least 5 minutes in a chair.  The auscultatory method should be used.  Caffeine, exercise, and smoking should be avoided for at least 30 minutes before BP measurement.  An appropriately sized cuff should be used.
  • 5. BP Measurement  At least two measurements should be made and the average recorded.  Clinicians should provide to patients their specific BP numbers and the BP goal of their treatment.
  • 6. Follow-up based on initial BP measurements for adults* *Without acute end-organ damagewww.nhlbi.nih.gov
  • 8. Prehypertension  SBP >120 mmHg and <139mmHg and/or  DBP >80 mmHg and <89 mmHg.  Prehypertension is not a disease category rather a designation for individuals at high risk of developing HTN.
  • 9. Pre-HTN  Individuals who are prehypertensive are not candidates for drug therapy but  Should be firmly and unambiguously advised to practice lifestyle modification  Those with pre-HTN, who also have diabetes or kidney disease, drug therapy is indicated if a trial of lifestyle modification fails to reduce their BP to 130/80 mmHg or less.
  • 10. Isolated Systolic Hypertension  Not distinguished as a separate entity as far as management is concerned.  SBP should be primarily considered during treatment and not just diastolic BP.  Systolic BP is more important cardiovascular risk factor after age 50.  Diastolic BP is more important before age 50.
  • 11. Frequency Distribution of Untreated HTN by Age Isolated Systolic HTN Isolated Diastolic HTN Systolic Diastolic HTN
  • 12. Hypertensive Crises  Hypertensive Urgencies: No progressive target-organ dysfunction. (Accelerated Hypertension)  Hypertensive Emergencies: Progressive end-organ dysfunction. (Malignant Hypertension)
  • 13. Hypertensive Urgencies  Severe elevated BP in the upper range of stage II hypertension.  Without progressive end-organ dysfunction.  Examples: Highly elevated BP without severe headache, shortness of breath or chest pain.  Usually due to under-controlled HTN.
  • 14. Hypertensive Emergencies  Severely elevated BP (>180/120mmHg).  With progressive target organ dysfunction.  Require emergent lowering of BP.  Examples: Severely elevated BP with: Hypertensive encephalopathy Acute left ventricular failure with pulmonary edema Acute MI or unstable angina pectoris Dissecting aortic aneurysm
  • 15. Types of Hypertension  Primary HTN: also known as essential HTN. accounts for 95% cases of HTN. no universally established cause known.  Secondary HTN: less common cause of HTN ( 5%). secondary to other potentially rectifiable causes.
  • 16. Causes of Secondary HTN  Common  Intrinsic renal disease  Renovascular disease  Mineralocorticoid excess  Sleep Breathing disorder  Uncommon  Pheochromocytoma  Glucocorticoid excess  Coarctation of Aorta  Hyper/hypothyroidism
  • 17. Secondary HTN-Clues in Medical History  Onset: at age < 30 yrs ( Fibromuscular dysplasi) or > 55 (athelosclerotic renal artery stenosis), sudden onset (thrombus or cholesterol embolism).  Severity: Grade II, unresponsive to treatment.  Episodic, headache and chest pain/palpitation (pheochromocytoma, thyroid dysfunction).  Morbid obesity with history of snoring and daytime sleepiness (sleep disorders)
  • 18. Secondary HTN-clues on Exam  Pallor, edema, other signs of renal disease.  Abdominal bruit especially with a diastolic component (renovascular)  Truncal obesity, purple striae, buffalo hump (hypercortisolism)
  • 19. Secondary HTN-Clues on Routine Labs  Increased creatinine, abnormal urinalysis ( renovascular and renal parenchymal disease)  Unexplained hypokalemia (hyperaldosteronism)  Impaired blood glucose ( hypercortisolism)  Impaired TFT (Hypo-/hyper- thyroidism)
  • 21. Renal Parenchymal Disease  Common cause of secondary HTN (2-5%)  HTN is both cause and consequence of renal disease  Multifactorial cause for HTN including disturbances in Na/water balance, vasodepressors/ prostaglandins imbalance  Renal disease from multiple etiologies.
  • 22. Renovascular HTN  Atherosclerosis 75-90% ( more common in older patients)  Fibromuscular dysplasia 10-25% (more common in young patients, especially females)  Other • Aortic/renal dissection • Takayasu’s arteritis • Thrombotic/cholesterol emboli • CVD • Post transplantation stenosis • Post radiation
  • 23. Complications of Prolonged Uncontrolled HTN  Changes in the vessel wall leading to vessel trauma and arteriosclerosis throughout the vasculature  Complications arise due to the “target organ” dysfunction and ultimately failure.  Damage to the blood vessels can be seen on fundoscopy.
  • 24. Target Organs  CVS (Heart and Blood Vessels)  The kidneys  Nervous system  The Eyes
  • 25. Effects On CVS  Ventricular hypertrophy, dysfunction and failure.  Arrhithymias  Coronary artery disease, Acute MI  Arterial aneurysm, dissection, and rupture.
  • 26. Effects on The Kidneys  Glomerular sclerosis leading to impaired kidney function and finally end stage kidney disease.  Ischemic kidney disease especially when renal artery stenosis is the cause of HTN
  • 27. Nervous System  Stroke, intracerebral and subaracnoid hemorrhage.  Cerebral atrophy and dementia
  • 28. The Eyes  Retinopathy, retinal hemorrhages and impaired vision.  Vitreous hemorrhage, retinal detachment  Neuropathy of the nerves leading to extraoccular muscle paralysis and dysfunction
  • 29. Retina Normal and Hypertensive Retinopathy Normal Retina Hypertensive Retinopathy A: Hemorrhages B: Exudates (Fatty Deposits) C: Cotton Wool Spots (Micro Strokes) A B C
  • 30. Stage I- Arteriolar Narrowing Arteriolar Narrowing
  • 31. Stage II- AV Nicking AV Nicking AV Nicking AV Nicking
  • 33. Stage III- Hemorrhages (H), Cotton Wool Spots and Exudats (E) H E
  • 34. Stage IV- Stage III+Papilledema
  • 35. Patient Evaluation Objectives  (1) To assess lifestyle and identify other cardiovascular risk factors or concomitant disorders that may affect prognosis and guide treatment  (2) To reveal identifiable causes of high BP  (3) To assess the presence or absence of target organ damage and CVD
  • 36. (1) Cardiovascular Risk factors  Hypertension  Cigarette smoking  Obesity (body mass index 30 kg/m2)≥  Physical inactivity  Dyslipidemia  Diabetes mellitus  Microalbuminuria or estimated GFR <60 mL/min  Age (older than 55 for men, 65 for women)  Family history of premature cardiovascular disease (men under age 55 or women under age 65)
  • 37. (2) Identifiable Causes of HTN  Sleep apnea  Drug-induced or related causes  Chronic kidney disease  Primary aldosteronism  Renovascular disease  Chronic steroid therapy and Cushing’s syndrome  Pheochromocytoma  Coarctation of the aorta  Thyroid or parathyroid disease
  • 38. (3) Target Organ Damage  Heart Left ventricular hypertrophy Angina or prior myocardial infarction Prior coronary revascularization Heart failure  Brain Stroke or transient ischemic attack  Chronic kidney disease  Peripheral arterial disease  Retinopathy
  • 39. History  Angina/MI Stroke: Complications of HTN, Angina may improve with b-blokers  Asthma, COPD: Preclude the use of b- blockers  Heart failure: ACE inhibitors indication  DM: ACE preferred  Polyuria and nocturia: Suggest renal impairment
  • 40. History-contd.  Claudication: May be aggravated by b- blockers, atheromatous RAS may be present  Gout: May be aggravated by diuretics  Use of NSAIDs: May cause or aggravate HTN  Family history of HTN: Important risk factor  Family history of premature death: May have been due to HTN
  • 41. History-contd.  Family history of DM : Patient may also be Diabetic  Cigarette smoker: Aggravate HTN, independently a risk factor for CAD and stroke  High alcohol: A cause of HTN  High salt intake: Advice low salt intake
  • 42. Examination  Appropriate measurement of BP in both arms  Optic fundi  Calculation of BMI ( waist circumference also may be useful)  Auscultation for carotid, abdominal, and femoral bruits  Palpation of the thyroid gland.
  • 43. Examination-contd.  Thorough examination of the heart and lungs  Abdomen for enlarged kidneys, masses, and abnormal aortic pulsation  Lower extremities for edema and pulses  Neurological assessment
  • 44. Routine Labs  EKG.  Urinalysis.  Blood glucose and hematocrit; serum potassium, creatinine ( or estimated GFR), and calcium.  HDL cholesterol, LDL cholesterol, and triglycerides.  Optional tests urinary albumin excretion. albumin/creatinine ratio.
  • 45. Goals of Treatment  Treating SBP and DBP to targets that are <140/90 mmHg  Patients with diabetes or renal disease, the BP goal is <130/80 mmHg  The primary focus should be on attaining the SBP goal.  To reduce cardiovascular and renal morbidity and mortality
  • 46. Benefits of Treatment  Reductions in stroke incidence, averaging 35–40 percent  Reductions in MI, averaging 20–25 percent  Reductions in HF, averaging >50 percent.
  • 48. Lifestyle Changes Beneficial in Reducing Weight  Decrease time in sedentary behaviors such as watching television, playing video games, or spending time online.  Increase physical activity such as walking, biking, aerobic dancing, tennis, soccer, basketball, etc.  Decrease portion sizes for meals and snacks.  Reduce portion sizes or frequency of consumption of calorie containing beverages.
  • 49. DASH Diet  Dietary approaches to Stop Hypertension  As effective as one medication
  • 50.

Editor's Notes

  1. Acute end-organ damage
  2. B
  3. AV Nicking
  4. P